U.S. markets closed

Blog Exposure - Teleflex Announces Launch of Expro Elite(TM) and Sympro Elite(TM) Snares for Peripheral Procedures in the US

Stock Monitor: Sensus Healthcare Post Earnings Reporting

LONDON, UK / ACCESSWIRE / February 07, 2018 / Active-Investors.com has just released a free research report on Teleflex Inc. (NYSE: TFX). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=TFX as the Company's latest news hit the wire. On February 05, 2018, the Company, which is a leading global provider of medical technologies for critical care and surgery, declared that it has received the 510(k) clearance by the US Food and Drug Administration (FDA), and is now set to commercially launch new versions of its Expro Elite™ and Sympro Elite™ Snares for manipulating interventional devices in peripheral procedures. Register today and get access to over 1000 Free Research Reports by joining our site below:


Active-Investors.com is currently working on the research report for Sensus Healthcare, Inc. (NASDAQ: SRTS), which also belongs to the Healthcare sector as the Company Teleflex. Do not miss out and become a member today for free to access this upcoming report at:


Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Teleflex most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:


About the Two Next-Generation Interventional Snares

Expro Elite™ and Sympro Elite™ Snares are the next-generation versions of the 0.035” interventional snares that were initially launched in the US in 2008 by Vascular Solutions, now a wholly-owned subsidiary of Teleflex.

While the Expro Elite™ Snare has a helical loop for capture in all directions, Sympro Elite™ has a simple 90-degree loop that remains coaxial to the vessel lumen for easy capture. Both these loops are available in 5, 10, 15, 25, and 35 mm loop diameters, which ensures clinical versatility in retrieving or repositioning intravascular devices. Both snares are 150 cm in length and are packaged one per box. Moreover, their preassembled, one-piece design ensures rapid deployment through any 0.035” compatible lumen. This eliminates exchanges and saves procedure time.

Products Created on Decade-long Experience

Stewart Strong, the President and General Manager at the Interventional business unit of Teleflex, expressed his pleasure on introducing Expro Elite™ and Sympro Elite™ Interventional Snares. He shared that these enhanced versions are built on a decade of reliable performance in the cath lab. Both Expro Elite™ and Sympro Elite™ have a significant pull force for superior handling in challenging procedures. These snares have a durable nitinol construction that retains their shape and adds strength. They also feature a radiopaque gold-plated tungsten coil and tip for enhanced visibility and a 1:1 torque response for controlled positioning. These features ensure greater control and maneuverability for better access to distal targets. Furthermore, these interventional Snares also have a unique locking handle that facilitates secure capture.

Products Meant for Usage in Cardiovascular System

  • The Expro Elite™ and Sympro Elite™ Snares are primarily meant for use in the cardiovascular system and the hollow viscus.
  • These help retrieve and manipulate objects using minimally invasive surgical procedures. Their manipulation procedures comprise retrieval or repositioning of intravascular foreign objects, such as coils, balloons, catheters, and guidewires within the cardiovascular system.
  • However, these devices are not intended for use in the coronary arteries or neuro-vasculature.

About Teleflex Inc.

Teleflex is a global provider of medical technologies designed to improve the health and quality of peoples' lives. The Company applies purpose-driven innovation to identify unmet medical needs. It has a diverse portfolio with solutions in areas such as vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine, and respiratory care.

Stock Performance Snapshot

February 06, 2018 - At Tuesday's closing bell, Teleflex's stock slightly rose 0.19%, ending the trading session at $261.95.

Volume traded for the day: 431.64 thousand shares, which was above the 3-month average volume of 279.31 thousand shares.

Stock performance in the last month – up 1.64%; previous three-month period – up 2.16%; past twelve-month period – up 53.98%; and year-to-date - up 5.28%

After yesterday's close, Teleflex's market cap was at $12.07 billion.

Price to Earnings (P/E) ratio was at 47.32.

The stock has a dividend yield of 0.52%.

The stock is part of the Healthcare sector, categorized under the Medical Instruments & Supplies industry. This sector was up 1.2% at the end of the session.


Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visithttp://active-investors.com/legal-disclaimer/.


For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors